Media coverage about Pulmatrix (NASDAQ:PULM) has trended somewhat positive this week, according to Alpha One. Alpha One, a subsidiary of Accern, identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pulmatrix earned a coverage optimism score of 0.10 on Alpha One’s scale. Alpha One also assigned media headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Alpha One Sentiment’s scoring:
- Pulmatrix’s Unique Inhaled Drug Candidate Has “Blockbuster” Potential, Says CFO Bill Duke (money.ca)
- Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN… (finanznachrichten.de)
- Pulmatrix Inc : Pulmatrix’s Unique Inhaled Drug Candidate Has “Blockbuster” Potential, Says CFO Bill Duke (4-traders.com)
- Today’s Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology (finance.yahoo.com)
Shares of Pulmatrix (NASDAQ:PULM) traded down 0.72% during trading on Friday, hitting $2.76. The stock had a trading volume of 915,740 shares. The firm has a 50 day moving average of $2.87 and a 200 day moving average of $2.25. Pulmatrix has a 1-year low of $0.50 and a 1-year high of $6.98. The company’s market capitalization is $52.78 million.
Pulmatrix (NASDAQ:PULM) last released its quarterly earnings results on Friday, May 5th. The biotechnology company reported ($0.21) EPS for the quarter. Pulmatrix had a negative return on equity of 91.67% and a negative net margin of 2,273.08%. Analysts expect that Pulmatrix will post ($4.13) EPS for the current fiscal year.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc and related companies with MarketBeat.com's FREE daily email newsletter.